MEG3 was shown to be downregulated in NSCLC, and it inhibits NSCLC cell apoptosis, invasion, migration, and metastasis, as well as increasing sensitivity to cisplatin [112,113,136]. This evidence concerns the gene MEG3 and non-small cell lung carcinoma.